JENSCARE-B(09877): LuX-ValvePlus has been approved by the Hong Kong Department of Health.

JENSCARE-B (09877) announced that the company's transcatheter tricuspid valve replacement system, LuX-ValvePlus, has recently received approval from the Hong Kong Special Administrative Region of the People's Republic of Chinas Department of Health. The company is actively promoting the commercialization of this product in the Hong Kong region. LuX-ValvePlus is the second transcatheter in situ tricuspid valve replacement product approved globally. Thanks to the product's differentiated advantages, ongoing therapy promotion efforts, and extensive clinical application experience, LuX-ValvePlus has gained wide market recognition. LuX-ValvePlus has now received registration approvals in multiple countries and regions, including Europe, the Middle East, and Asia-Pacific. The recent approval from the Hong Kong Department of Health further validates the product's potential in tricuspid regurgitation therapy. The company will continue to accelerate the global commercialization process of LuX-ValvePlus comprehensively to further achieve its long-term strategic goals.